PhaseV, a leader in AI/ML for clinical development, today announced the launch of its AI Conductor, a centralized platform that automates the entire clinical trial journey from protocol authoring to ...
Clinical Trials Arena on MSN
PhaseV unveils centralised platform to automate clinical trials
AI Conductor operates as an orchestration layer across PhaseV’s vertical AI platform.
As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review boards (“IRBs”) with defining, identifying, and reporting ...
The newly introduced AI-powered study build engine marks the first phase of ClinCapture's broader intelligent trial roadmap. By automating protocol translation, Captivate establishes a foundation for ...
Most protocol deviations start as human problems, not operational ones, but risk-based monitoring typically relies on lagging ...
Investigator-initiated trials are uniquely unsuited to a patchwork of Google Drive folders, Excel worksheets, and consumer-grade software. Industry sponsors deploy full ...
In the second of a two-part article, Gabrielle Faure-André and Stéphanie Garçon at Santarelli unpick EPO, UPC and French case law to assess the importance of clinical development timelines in ...
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date The ...
When discussing the future of clinical trials, people often focus on the promise of exciting new technologies, including artificial intelligence (AI) and predictive modeling. However, even the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results